AzTrials
AzTrials

Depressive Disorder, MajorNCT05988333

Psychoeducational Intervention for Families With a Member Affected by Major Depression

A study testing Psychoeducational Family Intervention and Informative intervention in people with Depressive Disorder, Major, run by University of Campania Luigi Vanvitelli at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Major depressive disorder (MDD) is the most common mental disorder. It can be a huge burden not only for the person affected by it, but also for his/her whole family. The goal of this clinical trial is to test the efficacy of a family supportive intervention called psychoeducational family intervention (PFI) compared… Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Depressive Disorder, Major
What is being tested?
Psychoeducational Family Intervention and Informative intervention
Could I receive a placebo?
No, everyone receives an active treatment
How many people
384 participants
Where
1 siteItaly
Study dates
27 Sep 2023to Sep 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • diagnosis of major depression, according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition;
  • ability to provide informed consent;
  • presence of at least one contact per month with the psychiatric clinic for at least six months prior to recruitment;
  • cohabitation with at least one family member.

Who cannot join

  • moderate or severe cognitive deficits, physical illnesses preventing the participation to the sessions or if they were hospitalization in the two months prior the enrollment

Trial locations and contacts

1 site in 1 country.

Mario Luciano, Doctor contact

+393490730150

mario.luciano@unicampania.it

Italy1 site, 1 recruiting
  • University of Campania L. Vanvitelli

    Naples, 80138

    Mario Luciano, Doctor

    Recruiting

Other trials in Italy

About this study

Official title: The Efficacy of Psychoeducational Family Intervention for Individuals With Major Depression: a Randomized Controlled Trial

Major depressive disorder (MDD) is the most common mental disorder. It can be a huge burden not only for the person affected by it, but also for his/her whole family. The goal of this clinical trial is to test the efficacy of a family supportive intervention called psychoeducational family intervention (PFI) compared to a brief informative intervention in families with a member affected by MDD. Families will participate in one of the two interventions for a period of 6 months more or less, and they will be asked to answer some questionnaires about how much MDD impacts on their everyday life and the patient's symptoms, in order to understand whether a more structured intervention such as PFI can be useful for families in order to better deal with this complicated illness.

Read the detailed description

The present paper is a no-profit, not-funded, national, multicentric, randomized-controlled trial with blinded outcome assessments, carried out in 24 Italian University outpatient units and coordinated by the Department of Mental and Physical Health and Preventive Medicine of the University of Campania Luigi Vanvitelli. In each center, 8 patients (and their families) and 8 controls will be recruited, for a total of 192 families assigned to the experimental group and 192 to the control group (total sample size = 384 families). Families are assessed at the baseline and 6-, 12- and 24-months post-randomization.

The primary aim of this study is to assess the efficacy of PFI in a group of patients with a diagnosis of MDD in terms of: 1) reduction of depressive symptoms; 2) improvement of psychosocial functioning; 3) improvement of social network. Furthermore, the efficacy of PFI will be also evaluated in terms of: 1) reduction of relapses and hospitalization in the 18 months following the end of the intervention; 2) improvement of adherence to pharmacological treatments and of patients' quality of life; 3) reduction of self-stigma; 4) improvement of coping strategies, family burden, and expressed emotion of family members of patients with major depression; 5) improvement of quality of life of family members. Finally, our study will investigate whether the presence of specific temperamental profiles and childhood traumas may mediate the effectiveness of the psychoeducational intervention.

The experimental intervention consists of the psychoeducational family intervention developed by Ian Falloon for the treatment of schizophrenia, which has been adapted to major depression and to the Italian context. The experimental intervention will be administered individually to each recruited family and consists of six phases: 1) engagement of the family unit; 2) individual assessment; 3) family assessment; 4) informative sessions; 5) communication skills sessions; 6) problem-solving skills sessions.

Patients and their relatives will be provided with information on: 1) the clinical characteristics of MDD, including onset and course, symptoms, prognosis, risk and protective factors; 2) available pharmacological and non-pharmacological treatments of MDD, its indications, side effects and strategies to cope with them, treatment duration, risk factors for relapse, and effects related to abrupt cessation of the therapy; 3) early signs of crisis, with the identification of the user's specific signs, completion and use of an ad-hoc form, the usefulness of their recognition for the prevention of episodes. A specific informative session on suicide has been developed, which will be administered only if the patients had a previous suicide attempt or report suicidal ideation during the intervention.

Each meeting is ideally divided into three phases: a first phase dedicated to clarifications and questions regarding the topics previously discussed; a second phase focused on the main topic of the meeting (the so-called "teaching phase"); and a final phase, in which the salient aspects discussed during the meeting are summarized, and "homework" is assigned.

The control group will receive an informative intervention consisting of five sessions, administered every 7-10 days, with the following content: healthy lifestyle habits (diet and nutrition), stress management, regulation of circadian rhythms, and management of medications' side effects.

The interventions will be discontinued if: 1) patients or their relatives will be unable to attend more than five consecutive psychoeducational sessions; 2) patients will be hospitalized or had any affective relapse during the intervention; or 3) patients or relatives withdraw their consent.

In both groups, patients will continue to receive the treatment usually provided in their center.

Trainings for the conduction of the intervention and for the use of assessment tools will be provided by the coordinating center. Two researchers (at least one being a psychiatrist) for each center will participate in a four-day training. During the training, a manual to conduct the experimental intervention is provided to participants, and several role-plays are organized. At least one researcher per center, not involved in the administration of the interventions, will be trained in the use of assessment tools and inter-rater reliability measurement. The training will include the following phases: a) presentation of the assessment instruments; b) group reading; c) simulations of administration; d) video-recorded interviews.

Work hypotheses is that the PFI will be effective in reducing severity of depressive symptoms, relapses and hospitalizations, and an improvement in adherence to pharmacological treatments, quality of life a reduction in internalized stigma, and an improvement in coping strategies.

Being tested
Psychoeducational Family Intervention, Informative intervention
Keywords
depression, caregiver, family, psychoeducation
Medical subject headings
Depressive Disorder, Major, Depression

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Psychoeducational Family InterventionOther

    Supportive intervention administered to families with a member affected by MDD

  • Informative interventionOther

    Informative intervention administered to families with a member affected by MDD

Study groups in NCT05988333
Study groupRoleWhat they receive
Psychoeducational Family InterventionExperimentalThe experimental intervention will be administered individually to each recruited family. Sessions will take place three times a month for a period ranging from 4 to 6 months (about 18 sessions in total). The number of sessions, as well as the frequency, may vary depending on the patient's clinical situation. Sessions will have an average duration of 60-90 minutes.
Receives: Other: Psychoeducational Family Intervention
Informative interventionActive comparatorThe informative intervention consists of five sessions, administered every 7-10 days.
Receives: Other: Informative intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Severity of depressive symptoms

    Hamilton Depression Rating Scale (HAM-D). The HAM-D includes 17 items. Of these, 8 items are scored from 0 (absent) to 4 (severe), while nine are scored from 0 to 2. The total score is performed by the sum of the items' scores, and ranges from 0 to 52 points.

    Measured: At baseline, after 6-, 12- and 24 months

  2. Psychosocial functioning

    Personal and Social Performance Scale (PSP). A total score can be attributed to score the overall patient's functioning, ranging from 0 to 100, with higher scores indicating higher functioning. Ratings are based mainly on the assessment of patient's functioning in four main areas: (1) socially useful activities; (2) personal and social relationships; (3) self-care; and (4) disturbing and aggressive behaviors.

    Measured: At baseline, after 6-, 12- and 24 months

  3. Severity of anxiety symptoms

    Hamilton Anxiety Rating Scale (HAM-A). It is a 14-items questionnaire developed to measure the severity of anxiety symptoms, both psychic (mental agitation and psychological distress) and somatic (physical complaints related to anxiety). The score for each item ranges from 0 (not present) to 4 (extreme severity).

    Measured: At baseline, after 6-, 12- and 24 months

  4. Social contacts

    Columbia Suicide Severity Rating Scale (C-SSRS). The clinician-administered version of the C-SSRS (screening version) will be administered. Individual's suicidal ideation is rated on a scale from 1 (wish to be dead) to 5 (active suicidal ideation with a specific plan and intent).

    Social Network Questionnaire (SNQ).

    Measured: At baseline, after 6-, 12- and 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Aug 2023
  2. Study start27 Sep 2023
  3. Primary completionSep 2026 (estimated)
  4. Study completionSep 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
384 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05988333
Sponsor's protocol ID
0012764/2023
Status last verified
Apr 2024
First submitted
4 Aug 2023
Last updated
19 Apr 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Psychoeducational Family Intervention and Informative intervention in people with Depressive Disorder, Major, run by University of Campania Luigi Vanvitelli at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 19 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Mario Luciano, Doctor (+393490730150, mario.luciano@unicampania.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Severity of depressive symptoms (time frame: At baseline, after 6-, 12- and 24 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Apr 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in